The University Hospital of Düsseldorf comprises 34 individual clinics and over 30 medical institutes, making the hospital one of the biggest medical institutions in the region. UDUS has a long-standing record in neuro-oncology and dendritic cell basic research and is well experienced in translational research for the development, regulatory approval, manufacturing and clinical application of cellular therapeutics, including dendritic cell vaccines. The Immunotherapy Laboratory at the Institute for Transplantation Diagnostics and Cell Therapeutics has established a GMP-compliant protocol, which allows for the successive generation of high purity immature and mature dendritic cells for antigen-loading and vaccination, respectively. The Centre for Neurooncology at the Department of Neurosurgery provides state-of-the-art care for neurooncological patients. With over 350 brain tumour operations per year, it is one of the largest and most experienced neuro-oncology centres in Germany. A dendritic cell vaccine is currently being evaluated  in a multicentre, randomised phase 2 clinical trial in newly diagnosed glioblastoma patients* , led by the Department of Neurosurgery and supported by the Coordinating Center for Clinical Trials at the university – a central unit for study management, monitoring, data management, pharmacovigilance, biometry and quality management of clinical trials – as well as the Department of Neuropathology – the brain tumour reference centre of the German Society of Neuropathology and Neuroanatomy.